Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA.

Secondary Objective(s):

• To assess the pharmacokinetics of CG400549 (960 mg daily) in subjects with cABSSSI due to MRSA

• To explore the in vitro susceptibility of cABSSSI-related bacteria to CG400549.

• To assess the safety of multiple doses of CG400459

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CrystalGenomics, Inc.
• Treatments: Methicillin

Criteria

Inclusion Criteria:

1. Diagnosis of major cutaneous abscess suspected or confirmed to be caused by a MRSA.

2. Signs and symptoms should include at least 2 of the following: purulent drainage or discharge, erythema, fluctuance, heat or localized warmth, edema/induration, pain or tenderness to palpation

Exclusion Criteria:

1. Prior systemic or topical antibacterial therapy

2. Severe sepsis or refractory shock